Supha Pharmachem (BOM:539561) EBIT: ₹170 Mil (TTM As of Sep. 2025)


BOM:539561 Supha Pharmachem Ltd BOM:539561
58 GF Score
Price ₹0.30
GF Value ₹1.53
Valuation Possible Value Trap
! 12 Warning Signs
View Full Analysis

What is Supha Pharmachem EBIT?

Supha Pharmachem BOM:539561 -3.23% 58 EBIT is ₹170 Mil as of Sep. 2025. GuruFocus rates BOM:539561 with a GF Score™ of 58/100 and a GF Value™ of ₹1.53 (Possible Value Trap). The stock has 12 warning signs investors should review.

Supha Pharmachem's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2025 was ₹106 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2025 was ₹170 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Supha Pharmachem's annualized ROC % for the quarter that ended in Sep. 2025 was 1.99%. Supha Pharmachem's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 8.39%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Supha Pharmachem's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2025 was 1.52%.


Supha Pharmachem  (BOM:539561) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Supha Pharmachem's annualized ROC % for the quarter that ended in Sep. 2025 is calculated as:

ROC % (Q: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Sep. 2025 ))/ count )
=294.792 * ( 1 - 17.38% )/( (0 + 12254.324)/ 1 )
=243.5571504/12254.324
=1.99 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=16231.81 - 3964.327 - ( 13.159 - max(0, 15179.823 - 16173.13+13.159))
=12254.324

Note: The Operating Income data used here is four times the quarterly (Sep. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Supha Pharmachem's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Sep. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=424.964/( ( (0 + max(0, 0)) + (58.322 + max(5004.638, 0)) )/ 1 )
=424.964/( ( 0 + 5062.96 )/ 1 )
=424.964/5062.96
=8.39 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6678.138 + 2607.912 + 22.929) - (3964.327 + 0 + 340.014)
=5004.638

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Supha Pharmachem's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2025 )
=169.595/11126.920
=1.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Supha Pharmachem EBIT Related Terms


Supha Pharmachem EBIT Historical Data

* Premium members only.

The historical data trend for Supha Pharmachem's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supha Pharmachem EBIT Chart

Supha Pharmachem Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.64 17.02 74.68 544.78 120.02

Supha Pharmachem Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.71 19.43 25.22 18.71 106.24

BOM:539561 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Supha Pharmachem's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supha Pharmachem EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supha Pharmachem's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Supha Pharmachem's EV-to-EBIT falls into.


BOM:539561
58GF Score
Supha Pharmachem Ltd BOM:539561
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supha Pharmachem EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹170 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹170 Mil mean?
Supha Pharmachem (BOM:539561) has a EBIT of ₹170 Mil as of Sep. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Supha Pharmachem.
Is Supha Pharmachem's EBIT too high?
Supha Pharmachem's current EBIT is ₹170 Mil. Overall, Supha Pharmachem has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Supha Pharmachem's EBIT compare to ZTS and UTHR?
Supha Pharmachem's EBIT of ₹170 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Supha Pharmachem. Supha Pharmachem's current EBIT is ₹170 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supha Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Supha Pharmachem (BOM:539561) is currently considered Possible Value Trap. The stock's GF Value™ is ₹1.53, compared to a current price of ₹0.30 — trading 80.4% below its estimated fair value. The current EBIT is ₹170 Mil. Supha Pharmachem's overall GF Score™ is 58/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Supha Pharmachem (BOM:539561), the current EBIT is ₹170 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supha Pharmachem (BOM:539561) Overvalued in 2026?

Based on GuruFocus' analysis, Supha Pharmachem stock appears to be undervalued. The current stock price of ₹0.30 is trading 80.4% below its estimated GF Value™ of ₹1.53. GuruFocus considers Supha Pharmachem to be Possible Value Trap.

Key valuation signals for BOM:539561:

  • EBIT: ₹170 Mil
  • GF Value™: ₹1.53 vs. price of ₹0.30 (80.4% below fair value)
  • GF Score™: 58/100 with 12 warning signs

No single metric tells the full story. See the BOM:539561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Supha Pharmachem Business Description

Address Saugbaug Road, Office No. 9, Behind Ravi Vihar Hotel, K Raheja Prime, Marol Industrial Estate, Andheri (East), Mumbai, MH, IND, 400059
Supha Pharmachem Ltd, formerly known as Remedium Lifecare Ltd, is engaged in the business of trading in API Intermediates (KSMs & CRMs) and various other raw materials used in API trading viz. Iso propyl Alcohol (IPA), Cyclohexane, DI Iso Propyl Amine (DIPA), Ethyl Acetate, Hydrazine Hydrate, Iso propyl Alcohol (IPA), Methylene Di Chloride, Potassium Carbonate Powder, Sodium Bi-Carbonate, Potassium Hydroxide Flakes, Sodium Chloride (Common Salt), Sodium Carbonate (SODA ASH), Amino isophthalic Acid, Tellurium(IV) Oxide, Grignard Reagent, Iodine, Selenium Metal Powder, Trimethyl Sulfoxonium Iodide (TMSI).
58GF Score

Get the complete analysis for BOM:539561

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹0.30
Price
₹1.53
GF Value